We are live on ! Find out more
CTNM icon

Contineum Therapeutics

63 hedge funds and large institutions have $207M invested in Contineum Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 19 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,500% more call options, than puts

Call options by funds: $232K | Put options by funds: $2K

361% more capital inflows, than outflows

Capital inflows: $41.3M | Capital outflows: $8.96M

8.8% more ownership

Funds ownership: 72.53% → 81.33% (+8.8%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

5% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 19

10% less funds holding

Funds holding: 70 → 63 (-7)

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

Holders
63
Holders Change
-7
Holders Change %
-10%
% of All Funds
0.82%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
14
Increased
18
Reduced
19
Closed
21
Calls
$232​K
Puts
$2​K
Net Calls
+$230​K
Net Calls Change
+$230​K

CTNM Hedge Fund Activity: Q3 2025 in Review

63 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q3 2025, worth a combined $207M — up 273% from $55.4M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CTNM and 14 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 18 added.

The largest buyer was RA Capital Management, opening a new position worth an estimated $17.1M. The largest seller was Baker Bros. Advisors, cutting an estimated $1.89M.

  • 63 institutional investors held Contineum Therapeutics (CTNM) as of Q3 2025, down from 70 in Q2 2025.
  • Funds reported $207M of Contineum Therapeutics stock for Q3 2025, up 273% quarter-over-quarter.
  • 14 funds opened new Contineum Therapeutics positions in Q3 2025 and 21 closed out, a net change of -7 holders.
  • The largest Contineum Therapeutics buyer in Q3 2025 was RA Capital Management, an estimated $17.1M added.
  • The largest Contineum Therapeutics seller in Q3 2025 was Baker Bros. Advisors, an estimated $1.89M sold.

Based on aggregated 13F filings for Q3 2025.